Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

How to: Clostridioides difficile infection in children

M. Krutova, TGJ. de Meij, F. Fitzpatrick, RJ. Drew, MH. Wilcox, EJ. Kuijper

. 2022 ; 28 (8) : 1085-1090. [pub] 20220310

Language English Country England, Great Britain

Document type Journal Article, Review

BACKGROUND: Clostridioides difficile infections (CDI) are traditionally attributed to an older adult patient group but children can also be affected. Although the causative pathogen is the same in both populations, the management of CDI may differ. OBJECTIVES: To discuss the current literature on CDI in the paediatric population and to provide CDI diagnostics and treatment guidance. SOURCES: The literature was drawn from a search of PubMed from January 2017 to July 2021. CONTENT: In the paediatric population, laboratory diagnostics for CDI should preferably be combined with laboratory diagnostics for other gastrointestinal pathogens. Coinfections of CDI are also possible. Though the detection of toxigenic C. difficile using a molecular assay may simply reflect colonisation rather than infection, detection of C. difficile free toxins A/B in faeces is much more indicative of true infection. CDI in children below 2 years of age and in the absence of risk factors is very difficult to diagnose and requires careful clinical judgement pending additional studies. Fidaxomicin has been shown to be superior to vancomycin with a sustained clinical response up to 30 days after the end of CDI treatment in children. Metronidazole is less effective than vancomycin in adults and there are no supporting data for its use in children. In recurrent CDI, treatment should be adjusted according to the drug or drug regimen used for the treatment of a previous episode(s). In multiple recurrent CDI, faecal microbiota transplantation can be effective. IMPLICATIONS: If CDI laboratory testing is indicated in children with diarrhoea, the likelihood of C. difficile colonisation and coinfection with other intestinal pathogens should be considered. The currently available data support a change in the treatment strategy of CDI in children.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024990
003      
CZ-PrNML
005      
20221031100210.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cmi.2022.03.001 $2 doi
035    __
$a (PubMed)35283312
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Krutova, Marcela $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Clostridioides difficile (ESGCD), Basel, Switzerland; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interaction (ESGHAMI). Electronic address: marcela.krutova@lfmotol.cuni.cz
245    10
$a How to: Clostridioides difficile infection in children / $c M. Krutova, TGJ. de Meij, F. Fitzpatrick, RJ. Drew, MH. Wilcox, EJ. Kuijper
520    9_
$a BACKGROUND: Clostridioides difficile infections (CDI) are traditionally attributed to an older adult patient group but children can also be affected. Although the causative pathogen is the same in both populations, the management of CDI may differ. OBJECTIVES: To discuss the current literature on CDI in the paediatric population and to provide CDI diagnostics and treatment guidance. SOURCES: The literature was drawn from a search of PubMed from January 2017 to July 2021. CONTENT: In the paediatric population, laboratory diagnostics for CDI should preferably be combined with laboratory diagnostics for other gastrointestinal pathogens. Coinfections of CDI are also possible. Though the detection of toxigenic C. difficile using a molecular assay may simply reflect colonisation rather than infection, detection of C. difficile free toxins A/B in faeces is much more indicative of true infection. CDI in children below 2 years of age and in the absence of risk factors is very difficult to diagnose and requires careful clinical judgement pending additional studies. Fidaxomicin has been shown to be superior to vancomycin with a sustained clinical response up to 30 days after the end of CDI treatment in children. Metronidazole is less effective than vancomycin in adults and there are no supporting data for its use in children. In recurrent CDI, treatment should be adjusted according to the drug or drug regimen used for the treatment of a previous episode(s). In multiple recurrent CDI, faecal microbiota transplantation can be effective. IMPLICATIONS: If CDI laboratory testing is indicated in children with diarrhoea, the likelihood of C. difficile colonisation and coinfection with other intestinal pathogens should be considered. The currently available data support a change in the treatment strategy of CDI in children.
650    _2
$a senioři $7 D000368
650    _2
$a antibakteriální látky $x terapeutické užití $7 D000900
650    _2
$a dítě $7 D002648
650    12
$a Clostridioides difficile $7 D016360
650    12
$a klostridiové infekce $x diagnóza $x epidemiologie $x terapie $7 D003015
650    _2
$a fidaxomicin $x terapeutické užití $7 D000077732
650    _2
$a lidé $7 D006801
650    _2
$a vankomycin $x terapeutické užití $7 D014640
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a de Meij, Tim G J $u Department of Paediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, the Netherlands
700    1_
$a Fitzpatrick, Fidelma $u Department of Clinical Microbiology, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Clostridioides difficile (ESGCD), Basel, Switzerland; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interaction (ESGHAMI)
700    1_
$a Drew, Richard J $u Irish Meningitis and Sepsis Reference Laboratory, Children's Health Ireland at Temple Street, Dublin, Ireland; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Clostridioides difficile (ESGCD), Basel, Switzerland
700    1_
$a Wilcox, Mark H $u Healthcare Associated Infection Research Group, Leeds Teaching Hospitals NHS Trust & University of Leeds, Leeds, United Kingdom; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Clostridioides difficile (ESGCD), Basel, Switzerland
700    1_
$a Kuijper, Ed J $u Department of Medical Microbiology and National Reference Laboratory for CDI, Leiden University Medical Centre and National Institute for Public Health and the Environment, Leiden, Netherlands; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Clostridioides difficile (ESGCD), Basel, Switzerland; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interaction (ESGHAMI)
773    0_
$w MED00001139 $t Clinical microbiology and infection $x 1469-0691 $g Roč. 28, č. 8 (2022), s. 1085-1090
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35283312 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100208 $b ABA008
999    __
$a ok $b bmc $g 1854605 $s 1176280
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 28 $c 8 $d 1085-1090 $e 20220310 $i 1469-0691 $m Clinical microbiology and infection $n Clin Microbiol Infect $x MED00001139
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...